1. Increased expression of activated endothelial nitric oxide synthase contributes to antiandrogen resistance in prostate cancer cells by suppressing androgen receptor transactivation
   Shan Yu et al, 2013, Cancer Letters CrossRef
2. Vinorelbine and capecitabine in anthracycline- and/or taxane-pretreated metastatic breast cancer: sequential or combinational?
   Jian Zhang et al, 2013, Cancer Chemother Pharmacol CrossRef
3. CCAAT/Enhancer binding protein β controls androgen-deprivation-induced senescence in prostate cancer cells
   D J Barakat et al, 2015, Oncogene CrossRef
4. Substitution of anti-androgens and tegafur-uracil combination therapy for castration-resistant prostate cancer: Results of a multi-center randomized phase II study
   MASAYUKI TAKAHASHI et al, 2013 CrossRef
5. One Size Fits All in Prostate Cancer: A Story Tale Whose Time has Come and Gone
   Ammad Ahmad Farooqi et al, 2011, The International Journal of Biological Markers CrossRef
6. Synthesis, characterization and anti-tumor activity of Pd(II) complexes with 4,5-benzo-3H-1,2-dithiole-3-thione
   Subhi A. Al-Jibori et al, 2019, Transit Met Chem CrossRef
7. HepaCAM inhibits the malignant behavior of castration-resistant prostate cancer cells by downregulating Notch signaling and PF-3084014 (a γ-secretase inhibitor) partly reverses the resistance of refractory prostate cancer to docetaxel and enzalutamide in vitro.
   Zhongbo Du et al, 0 CrossRef
8. Systemic delivery of aptamer–drug conjugates for cancer therapy using enzymatically generated self-assembled DNA nanoparticles
   Binh Thanh Tran et al, 2020, Nanoscale CrossRef
9. Quercetin potentiates the chemosensitivity of MCF-7 breast cancer cells to 5-fluorouracil
   Fatemeh Mawalizadeh et al, 2021, Mol Biol Rep CrossRef
10. Current World Literature
    , 2012 CrossRef
11. Updates on Overcoming Bicalutamide Resistance: A Glimpse into Resistance to a Novel Antiandrogen
    Mehrnaz Izady et al, 2024, ACS Pharmacol. Transl. Sci. CrossRef